Compare TU & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TU | EXAS |
|---|---|---|
| Founded | 1993 | 1995 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical Specialities |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0B | 19.3B |
| IPO Year | N/A | N/A |
| Metric | TU | EXAS |
|---|---|---|
| Price | $13.63 | $102.31 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 19 |
| Target Price | $18.17 | ★ $84.27 |
| AVG Volume (30 Days) | ★ 4.9M | 2.1M |
| Earning Date | 02-12-2026 | 02-18-2026 |
| Dividend Yield | ★ 8.86% | N/A |
| EPS Growth | ★ 24.25 | N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $14,679,551,147.00 | $3,082,033,000.00 |
| Revenue This Year | $2.94 | $19.40 |
| Revenue Next Year | $2.40 | $13.51 |
| P/E Ratio | $24.04 | ★ N/A |
| Revenue Growth | 2.42 | ★ 14.47 |
| 52 Week Low | $12.54 | $38.81 |
| 52 Week High | $16.74 | $102.66 |
| Indicator | TU | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 60.20 | 79.65 |
| Support Level | $13.27 | $102.00 |
| Resistance Level | $13.64 | $102.56 |
| Average True Range (ATR) | 0.19 | 0.33 |
| MACD | 0.06 | -0.54 |
| Stochastic Oscillator | 94.72 | 70.31 |
Telus is one of the Big Three wireless service providers in Canada, with over 10 million mobile phone subscribers nationwide constituting almost 30% of the total market. It is the incumbent local exchange carrier in the western Canadian provinces of British Columbia and Alberta, where it provides internet, television, and landline phone services. It also has a small wireline presence in eastern Quebec. Mostly because of recent acquisitions, more than 20% of Telus' sales now come from nontelecom businesses, most notably in the international business services, health, security, and agriculture industries. The firm has a 55% economic stake in Telus International.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.